Natalizumab
- Generic Name
- Natalizumab
- Brand Names
- Tysabri, Tyruko
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 189261-10-7
- Unique Ingredient Identifier
- 3JB47N2Q2P
- Background
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for mu...
- Indication
Natalizumab is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
...
- Associated Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Severe Crohn's Disease, Moderate Crohn’s Disease
- Associated Therapies
- -
Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT03811886
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Biogen
- Target Recruit Count
- 585
- Registration Number
- NCT03689972
- Locations
- 🇧🇪
CHU de Tivoli, La Louvière, Belgium
🇺🇸MS Center of California, Laguna Hills, California, United States
🇺🇸UCI MIND, Irvine, California, United States
Towards Personalized Dosing of Natalizumab in Multiple Sclerosis
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 61
- Registration Number
- NCT03516526
- Locations
- 🇳🇱
Rijnstate Hospital, Arnhem, Netherlands
🇳🇱St. Antonius Hospital, Utrecht, Netherlands
🇳🇱VU medical center, Amsterdam, Netherlands
Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 67
- Registration Number
- NCT03283371
- Locations
- 🇺🇸
Research Site, Renton, Washington, United States
Inflammatory Response In Schizophrenia
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- King's College London
- Target Recruit Count
- 66
- Registration Number
- NCT03093064
- Locations
- 🇬🇧
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
- First Posted Date
- 2017-02-08
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 30
- Registration Number
- NCT03046251
- Locations
- 🇺🇸
SUNY Buffalo, Buffalo, New York, United States
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 277
- Registration Number
- NCT02730455
- Locations
- 🇬🇧
Research Site, Stoke on Trent, Staffordshire, United Kingdom
Clinical Disease Activity With Long Term Natalizumab Treatment
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 277
- Registration Number
- NCT02677077
- Locations
- 🇨🇿
Research Site, Prague, Czechia
🇧🇪Research Site 2, Brussels, Belgium
🇧🇪Research Site 1, Brussels, Belgium
Natalizumab in Inclusion Body Myositis (IBM)
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Phoenix Neurological Associates, LTD
- Target Recruit Count
- 6
- Registration Number
- NCT02483845
- Locations
- 🇺🇸
Phoenix Neurological Insitutute, Phoenix, Arizona, United States
Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab
- First Posted Date
- 2015-03-12
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 48
- Registration Number
- NCT02386566
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
🇨🇭Research site - private practice, Luzern, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.